Business Wire

MITSUBISHI-HITACHI-POWER

2.4.2020 04:02:07 CEST | Business Wire | Press release

Share
MHPS: World’s Most Efficient Power Plant Is Synced to the Grid and Operating at Full Load, Ahead of Schedule

Mitsubishi Hitachi Power Systems, Ltd. (MHPS) has begun commissioning of T-Point 2, its new combined cycle power plant validation facility at Takasago Works in Hyogo Prefecture, Japan. Replacing the iconic T-Point, the facility will accelerate MHPS’ industry-leading technology and enable more robust validation of advanced-class gas turbines (ACGTs) such as the 1650°C-class JAC model and 1700°C-class ultrahigh-temperature models. Like its predecessor, T-Point 2 stands apart as the only facility in the world that performs full-scale long-term reliability verification for gas turbines. Connected to the actual grid, it is the only plant of its type in the world to function as both a technology demonstrator and an electric power producer and supplier. Also housed within Takasago Works are centers for R&D, design, manufacturing, and short-term component testing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200401005834/en/

“Through the years, we have proven our ability to develop and manufacture the most cutting-edge solutions for the power generation industry,” said Mr. Ken Kawai, President and CEO, MHPS. “Building on the legacy of the original T-Point, T-Point 2 will enable us to widen our footprint as the preferred solutions partner to meet ever-changing power generation requirements around the world.”

Engineering the next generation of gas turbines
Once commercial operations begin in July 2020, T-Point 2 is expected to achieve power output of over 566 MW (60Hz), with nearly 64% efficiency, 99.5% reliability and a world-first turbine inlet temperature of 1650°C – raising industry standards for gas turbine combined cycle performance globally. This improved performance is possible due to the advanced engineering of the upgraded J-Series Air-Cooled (JAC) model, which is the first gas turbine being validated at T-Point 2.

The new facility features a triple-casing steam turbine, augmenting overall system efficiency through a multiplier effect with the JAC gas turbine. This greater efficiency reduces carbon emissions and heat loss, significantly reducing the environmental impact of T-Point 2.

“The prototype validation system established by MHPS has given our customers the clear assurance that they are receiving the highest caliber and most reliable energy solutions in the market,” said Mr. Junichiro Masada, Senior Vice President and Senior General Manager of Gas Turbine Technology & Products Integration Division, MHPS. “The launch of T-Point 2 is testament to MHPS’ commitment to deliver industry-leading power generation technology and customer service underpinned by best-in-class methods for performance and durability verification.”

MHPS will use the facility to conduct validation of the next-generation 1700°C-class ultrahigh-temperature gas turbines, steam turbine upgrades, air-cooled condenser technology, generators, and static frequency converters.

Bringing power generation to the digital age
Work is underway to install and train advanced artificial intelligence technology at T-Point 2, which will feature the MHPS-TOMONI® suite of digital solutions. During the 8,000 hour durability demonstration period, MHPS will also be training its AI apps, allowing T-Point 2 to eventually become the world’s first autonomous combined cycle power plant. This will catapult power generation into a future where digital technologies are fully integrated into plant operations, allowing plant owners to leverage data to optimize performance, enable condition-based predictive maintenance for equipment, selectively automate operation and maintenance (O&M) decision-making, and reduce risk.

With these building blocks, MHPS will remotely monitor and manage total plant performance; remotely operate the plant in coordination with grid and fleet-wide energy management objectives; and utilize sensor and control system data to make smarter operation decisions in real time. MHPS-TOMONI® solutions powered by advanced technologies such as artificial intelligence and machine learning will enable MHPS to automate O&M decision-making to maximize the profitability of existing and future GTCC plants.

About Mitsubishi Hitachi Power Systems, Ltd.
Mitsubishi Hitachi Power Systems, Ltd. (MHPS), headquartered in Yokohama, Japan, is a joint venture formed in February 2014 by Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in thermal power generation systems and other related businesses. MHPS today ranks among the world’s leading suppliers of equipment and services to the power generation market, backed by 100 billion yen in capital and approximately 20,000 employees worldwide. The Company’s products include GTCC (gas turbine combined-cycle) and IGCC (integrated coal gasification combined-cycle) power plants, gas/coal/oil-fired (steam) power plants, boilers, generators, gas and steam turbines, geothermal power plants, AQCS (air quality control systems), power plant peripheral equipment and solid-oxide fuel cells (SOFC). For more information, please visit the Company's website at https://www.mhps.com . Follow us at https://twitter.com/MHPS_Global , or http://www.linkedin.com/showcase/mhps

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye